Qualigen Therapeutics

Yahoo Finance • 2 days ago

Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)

New York, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $41 mill... Full story

Yahoo Finance • 3 days ago

Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto

Carlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or “the Company”) today announced the successful closing of a $41 million private investment in public equity (PIPE) financing led by... Full story

Yahoo Finance • 3 days ago

Faraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco Strategy

QLGN is expected to rebrand as CXC10 soon, reflecting its new strategic direction around crypto and web3 business. LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”... Full story

Yahoo Finance • 10 days ago

This Penny Stock Is Surging Big Time on a Tie-Up With Faraday Future and a Push Into Crypto. Should You Buy Its Shares Here?

Qualigen Therapeutics (QLGN) [https://www.barchart.com/quotes/QLGN] shares soared about 200% on Monday at the peak after the biotech company secured a $41 million investment from Faraday Future (FFAI) [https://www.barchart.com/quotes/FFAI]... Full story

Yahoo Finance • 11 days ago

Qualigen To Focus On Driving Growth In Crypto, Web3 - Stock Surges 200%

(RTTNews) - Shares of Qualigen Therapeutics Inc. (QLGN) are up over 200% in premarket trading on Monday, following a $41 million strategic investment by Faraday Future Intelligent Electric Inc. (FFAI), a California-based global shared inte... Full story

Yahoo Finance • 11 days ago

Faraday Future announces investment of $41M in Qualigen Therapeutics

* Faraday Future (NASDAQ:FFAI [https://seekingalpha.com/symbol/FFAI]) said on Sunday that it is strategically investing [https://seekingalpha.com/pr/20239048-faraday-future-announced-a-total-strategic-investment-of-41-million-in-qualigen... Full story

Yahoo Finance • 11 days ago

Faraday Future Announced a Total Strategic Investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) During its Annual 919 Event, for its Crypto Business Focusing on Three Growth Engines

Faraday Future is making an investment of approximately $30 million in Qualigen Therapeutics (“QLGN”); FF Founder and Co-CEO YT Jia will invest approximately $4 million (via an FFGP loan) in QLGN with a two-year lockup.The strategic invest... Full story

Yahoo Finance • 13 days ago

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE Transaction

LOS ANGELES and CARLSBAD, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem... Full story

Yahoo Finance • 13 days ago

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction

LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company,... Full story

Yahoo Finance • 2 months ago

Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status

CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from the staff of the Nasdaq Listing Qualifications office of the Nasdaq Stock Market, L... Full story

Yahoo Finance • 2 months ago

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential... Full story

Yahoo Finance • 3 months ago

Qualigen Therapeutics secures global patents for cancer drug QN-302

CARLSBAD, Calif. - Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a small-cap biotech with a market capitalization of $5.77 million, announced Wednesday that it has secured multiple patents for its cancer drug QN-302 across Europe, India, Chin... Full story

Yahoo Finance • 3 months ago

Qualigen Granted New Patents Covering 25 Countries

Qualigen Therapeutics, Inc. CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an update on patents granted in the first six months of 2025. The paten... Full story

Yahoo Finance • 4 months ago

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq... Full story

Yahoo Finance • 2 years ago

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary e... Full story

Yahoo Finance • 2 years ago

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designa... Full story

Yahoo Finance • 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company... Full story

Yahoo Finance • 2 years ago

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-s... Full story

Yahoo Finance • 2 years ago

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designa... Full story

Yahoo Finance • 2 years ago

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately$5 million in all cash transaction to support advancement of therapeu... Full story